CLINICAL TRIALS PROFILE FOR DYNACIRC
✉ Email this page to a colleague
All Clinical Trials for DYNACIRC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00593463 ↗ | Drug Discrimination in Methadone-Maintained Humans Study 1 | Completed | University of Arkansas | Phase 1 | 2006-09-01 | This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions. |
| NCT00909545 ↗ | Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease | Completed | Michael J. Fox Foundation for Parkinson's Research | Phase 2 | 2009-07-01 | The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies. |
| NCT00909545 ↗ | Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease | Completed | Northwestern University Dixon Fund | Phase 2 | 2009-07-01 | The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies. |
| NCT00909545 ↗ | Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease | Completed | The Parkinson Study Group | Phase 2 | 2009-07-01 | The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies. |
| NCT00909545 ↗ | Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease | Completed | Northwestern University | Phase 2 | 2009-07-01 | The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies. |
| NCT03083353 ↗ | Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation | Recruiting | National Institute on Drug Abuse (NIDA) | Early Phase 1 | 2020-01-22 | The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DYNACIRC
Condition Name
Clinical Trial Locations for DYNACIRC
Trials by Country
Clinical Trial Progress for DYNACIRC
Clinical Trial Phase
Clinical Trial Sponsors for DYNACIRC
Sponsor Name
